| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Caffeine is a natural chemical with stimulant effects. It is found in coffee, tea, cola, cocoa, guarana, yerba mate, and over 60 other products. Caffeine (CAF; 1,3,7-trimethylxanthine) — dietary methylxanthine (natural product / drug) found in coffee/tea/cacao and used in OTC stimulants and some analgesic combinations. Sources: coffee/tea, supplements, OTC meds. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Rapid oral absorption; widely distributed (including CNS); hepatic metabolism (CYP1A2) with large inter-individual variability; tolerance develops with habitual use. In-vitro vs oral exposure: Many “anti-cancer” mechanisms rely on supra-physiologic concentrations (PDE inhibition, checkpoint override) vs typical dietary plasma levels; clinically relevant mechanism is adenosine antagonism. This is a major translation constraint. Physiologic human exposures after ordinary intake are in the low micromolar range relevant to adenosine receptor occupancy, whereas many anticancer in-vitro effects commonly attributed to caffeine, especially PDE inhibition, Ca²⁺ release, and checkpoint override, usually require far higher concentrations, often approaching high-micromolar to millimolar ranges. Clinical evidence status: Extensive human data for alertness/performance; oncology evidence is mainly epidemiologic + preclinical (no anticancer indication). Natural stimulant-Caffeine appears to interact with several pathways relevant to cancer biology—including adenosine receptor signaling, DNA damage response, cell cycle regulation, apoptosis, PI3K/Akt/mTOR, and NF-κB —Its overall impact likely depends on the cancer type, stage, microenvironment, and the dosage administered Caffeine — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Caffeine — AD relevance: Strong mechanistic fit via adenosine A2A antagonism (synaptic plasticity + neuroinflammation modulation). Human data support acute attention benefits; dementia/AD risk signals are largely observational (not disease-modifying approval). Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Rapid CNS penetration; effects are acute (minutes–hours) but chronic patterns depend on tolerance and sleep timing. Clinical evidence status: Supportive (symptom/attention); AD disease-modifying efficacy not established. Caffeine — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: HalifaxProj(inhibit) CGL-CS TCGA |
| Type: |
| Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses. Anti-inflammatory cytokine. In normal tissues, TGF-β plays an essential role in cell cycle regulation, immune function, and tissue remodeling. - In early carcinogenesis, TGF-β typically acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis. In advanced cancers, cells frequently become resistant to the growth-inhibitory effects of TGF-β. - TGF-β then switches roles and promotes tumor progression by stimulating epithelial-to-mesenchymal transition (EMT), cell invasion, metastasis, and immune evasion. Non-canonical (Smad-independent) pathways, such as MAPK, PI3K/Akt, and Rho signaling, also contribute to TGF-β-mediated responses. Elevated levels of TGF-β have been detected in many advanced-stage cancers, including breast, lung, colorectal, pancreatic, and prostate cancers. - The switch from a tumor-suppressive to a tumor-promoting role is often associated with increased TGF-β production and activation in the tumor microenvironment. High TGF-β expression or signaling activity is frequently correlated with aggressive disease features, resistance to therapy, increased metastasis, and poorer overall survival in many cancer types. |
| 1206- | Caff, | Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices |
| - | in-vitro, | NA, | NA | - | ex-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:52 Target#:304 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid